Tasly Pharmaceutical Group Co Ltd banner

Tasly Pharmaceutical Group Co Ltd
SSE:600535

Watchlist Manager
Tasly Pharmaceutical Group Co Ltd Logo
Tasly Pharmaceutical Group Co Ltd
SSE:600535
Watchlist
Price: 13.89 CNY 0.51% Market Closed
Market Cap: ¥20.8B

Balance Sheet

Balance Sheet Decomposition
Tasly Pharmaceutical Group Co Ltd

Balance Sheet
Tasly Pharmaceutical Group Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2001 Dec-2002 Dec-2003 Dec-2004 Dec-2005 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
129
691
607
391
566
619
268
404
556
1 604
1 526
1 039
956
1 115
1 081
1 329
1 499
2 691
1 519
1 816
2 104
2 927
3 625
2 390
Cash
0
0
0
0
0
0
0
0
0
0
0
5
3
0
1
0
0
1
1
0
2 104
2 927
3 625
2 390
Cash Equivalents
129
691
607
391
566
619
268
404
556
1 604
1 526
1 034
953
1 115
1 080
1 329
1 499
2 690
1 518
1 816
0
0
0
0
Short-Term Investments
0
0
0
10
90
0
0
0
0
0
0
26
85
0
0
0
0
0
59
143
1 487
1 125
301
525
Total Receivables
129
110
314
399
429
623
708
705
808
902
1 594
2 307
3 396
5 004
6 578
7 247
10 395
11 606
11 465
5 655
3 845
3 394
2 163
2 014
Accounts Receivables
79
62
235
220
270
290
392
519
536
564
808
1 313
2 052
3 559
4 643
4 876
6 748
8 272
8 431
1 872
1 295
896
688
780
Other Receivables
50
48
79
179
159
333
316
186
272
338
786
994
1 344
1 445
1 935
2 371
3 647
3 334
3 034
3 783
2 550
2 498
1 475
1 234
Inventory
31
49
78
84
93
200
244
313
388
561
745
1 064
1 265
1 477
1 764
2 012
2 231
2 397
2 547
1 354
1 548
1 532
1 748
1 712
Other Current Assets
63
45
124
214
147
82
81
89
89
105
119
198
176
192
476
587
924
1 126
953
270
265
281
896
671
Total Current Assets
351
894
1 123
1 097
1 325
1 524
1 301
1 511
1 841
3 172
3 984
4 635
5 879
7 788
9 897
11 176
15 049
17 819
16 543
9 237
9 249
9 259
8 733
7 311
PP&E Net
229
304
584
864
1 177
1 154
1 342
1 345
1 367
1 415
1 765
2 356
3 073
3 516
3 688
3 908
3 961
3 944
4 011
3 889
4 168
3 989
3 812
3 669
PP&E Gross
229
304
584
864
1 177
1 154
1 342
1 345
1 367
1 415
1 765
2 356
3 073
3 516
3 688
3 908
3 961
3 944
4 011
3 889
4 168
3 989
3 812
3 669
Accumulated Depreciation
15
35
66
107
156
221
315
396
480
566
667
795
1 000
1 190
1 356
1 613
1 914
2 218
2 568
2 744
3 149
3 550
3 898
4 232
Intangible Assets
14
50
44
100
89
338
355
357
298
305
369
490
587
681
840
940
1 046
1 565
1 809
1 646
1 626
1 587
2 027
2 050
Goodwill
0
0
0
0
0
15
15
15
15
15
45
40
154
139
133
138
138
176
143
16
167
16
16
0
Note Receivable
0
0
0
0
0
0
0
0
0
0
0
111
82
94
0
0
0
0
0
0
0
0
0
0
Long-Term Investments
1
1
18
128
137
186
200
201
476
496
418
416
412
409
530
685
1 054
1 362
1 209
1 535
1 229
1 511
2 054
1 858
Other Long-Term Assets
0
2
9
12
27
69
18
20
28
50
53
93
212
294
324
280
283
306
299
170
103
116
73
89
Other Assets
0
0
0
0
0
15
15
15
15
15
45
40
154
139
133
138
138
176
143
16
167
16
16
0
Total Assets
595
N/A
1 251
+110%
1 777
+42%
2 201
+24%
2 754
+25%
3 286
+19%
3 231
-2%
3 448
+7%
4 025
+17%
5 453
+35%
6 634
+22%
8 140
+23%
10 399
+28%
12 921
+24%
15 413
+19%
17 126
+11%
21 532
+26%
25 172
+17%
24 014
-5%
16 494
-31%
16 542
+0%
16 478
0%
16 714
+1%
14 976
-10%
Liabilities
Accounts Payable
29
41
52
39
117
183
183
178
157
193
451
711
888
1 322
1 447
1 857
2 067
2 140
2 112
480
531
886
573
607
Accrued Liabilities
22
30
53
72
77
63
100
101
124
131
156
198
257
262
285
391
425
323
244
239
217
248
192
183
Short-Term Debt
215
4
358
579
689
438
483
938
1 286
1 354
1 399
1 708
2 702
4 755
4 482
5 123
7 753
4 687
3 450
843
387
191
815
702
Current Portion of Long-Term Debt
0
0
0
36
10
42
102
0
2
2
225
40
61
57
15
400
404
589
2 189
1 101
399
529
521
634
Other Current Liabilities
32
29
53
75
43
566
70
19
43
100
507
304
1 233
370
358
388
691
777
662
169
322
281
269
224
Total Current Liabilities
298
104
516
801
937
1 292
939
1 236
1 611
1 780
2 739
2 962
5 141
6 767
6 586
8 159
11 340
8 516
8 657
2 832
1 855
2 135
2 370
2 350
Long-Term Debt
50
36
36
0
224
227
195
100
225
225
63
501
869
812
798
400
892
5 156
3 232
1 020
1 116
1 451
1 496
322
Deferred Income Tax
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
23
42
23
0
0
Minority Interest
8
24
87
174
257
294
183
181
138
118
172
253
311
231
237
243
320
675
732
412
333
265
322
208
Other Liabilities
0
19
24
25
29
21
19
19
18
23
57
178
210
274
321
361
326
292
257
235
215
178
159
193
Total Liabilities
357
N/A
183
-49%
663
+262%
1 001
+51%
1 446
+44%
1 834
+27%
1 336
-27%
1 536
+15%
1 992
+30%
2 146
+8%
3 030
+41%
3 894
+29%
6 532
+68%
8 083
+24%
7 943
-2%
9 162
+15%
12 877
+41%
14 638
+14%
12 882
-12%
4 521
-65%
3 560
-21%
4 052
+14%
4 346
+7%
3 073
-29%
Equity
Common Stock
140
190
285
285
285
285
488
488
488
516
516
516
1 033
1 033
1 080
1 080
1 080
1 513
1 513
1 513
1 513
1 500
1 500
1 494
Retained Earnings
99
217
263
349
457
595
751
860
982
1 237
1 538
2 090
2 555
3 562
4 619
5 342
6 113
7 226
7 730
8 359
10 222
9 382
9 929
9 898
Additional Paid In Capital
0
661
566
567
567
572
657
564
564
1 554
1 551
1 640
280
244
1 771
1 544
1 476
1 930
1 991
2 321
1 530
1 439
958
459
Unrealized Security Profit/Loss
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
141
5
38
Treasury Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
87
100
195
251
106
106
0
Other Equity
0
0
0
0
0
0
1
1
1
1
2
2
2
2
2
3
16
48
2
25
32
70
83
90
Total Equity
239
N/A
1 068
+347%
1 114
+4%
1 200
+8%
1 308
+9%
1 452
+11%
1 896
+31%
1 912
+1%
2 033
+6%
3 307
+63%
3 604
+9%
4 245
+18%
3 867
-9%
4 838
+25%
7 469
+54%
7 964
+7%
8 655
+9%
10 534
+22%
11 132
+6%
11 972
+8%
12 981
+8%
12 426
-4%
12 368
0%
11 903
-4%
Total Liabilities & Equity
595
N/A
1 251
+110%
1 777
+42%
2 201
+24%
2 754
+25%
3 286
+19%
3 231
-2%
3 448
+7%
4 025
+17%
5 453
+35%
6 634
+22%
8 140
+23%
10 399
+28%
12 921
+24%
15 413
+19%
17 126
+11%
21 532
+26%
25 172
+17%
24 014
-5%
16 494
-31%
16 542
+0%
16 478
0%
16 714
+1%
14 976
-10%
Shares Outstanding
Common Shares Outstanding
941
1 277
1 277
1 277
1 277
1 277
1 366
1 366
1 366
1 446
1 446
1 446
1 446
1 446
1 513
1 513
1 513
1 513
1 513
1 513
1 499
1 494
1 494
1 494
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett